• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Stoke Therapeutics Inc.

    4/22/26 4:09:16 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STOK alert in real time by email
    DEFA14A 1 d79682ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 14A

    (Rule 14a-101)

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    STOKE THERAPEUTICS, INC.

    (Name of Registrant as Specified In Its Charter)

    N/A

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


    LOGO

    Your Vote Counts! STOKE THERAPEUTICS, INC. 2026 Annual Meeting Vote by June 2, 2026 11:59 PM ET STOKE THERAPEUTICS, INC. 45 WIGGINS AVE. BEDFORD, MA 01730 V95129-P47897 You invested in STOKE THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 3, 2026. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 20, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your 16-digit control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Vote Virtually at the Meeting* Point your camera here and June 3, 2026 9:00 AM ET vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/STOK2026 *Please check the meeting materials for any special requirements for meeting attendance. 


    LOGO

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Voting Items Recommends 1. Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal. Nominees: For All 01) G. Clare Kahn, Ph.D. 02) Adrian Krainer, Ph.D. 03) Julie Anne Smith 2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year For ending December 31, 2026. 3. To approve, on an advisory basis, the compensation of the Company’s named executive officers. For NOTE: Stockholders may be asked to consider and vote upon such other business as may properly come before the meeting or any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V95130-P47897

    Get the next $STOK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STOK

    DatePrice TargetRatingAnalyst
    7/13/2026$44.00Buy
    Goldman
    2/24/2026$40.00Outperform
    Wolfe Research
    2/5/2026$60.00Buy
    Guggenheim
    1/5/2026$35.00Buy
    Chardan Capital Markets
    7/18/2025$30.00Buy
    Jefferies
    12/20/2024$24.00Buy
    Chardan Capital Markets
    10/14/2024$18.00Outperform
    Leerink Partners
    3/26/2024Market Perform → Outperform
    TD Cowen
    More analyst ratings

    $STOK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on July 15, 2026, it granted stock options to purchase shares of common stock to Thomas McCauley, the Company’s newly-appointed Chief Scientific Officer, and seven other new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted Mr. McCauley stock options to purchase 225

    7/16/26 4:01:00 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer

    –Dr. McCauley brings more than 25 years of experience building high-performing R&D organizations and translating early scientific discoveries into new medicines for people with severe diseases– Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Thomas McCauley, Ph.D., has been appointed Chief Scientific Officer. Dr. McCauley joins Stoke with more than 25 years of experience leading high-performing R

    7/13/26 7:30:00 AM ET
    $STOK
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

    —Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027— —Phase 3 data readout anticipated in the third quarter of 2027 to complete the rolling U.S. NDA submission in the second half of 2027— Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced the completion of enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen. Stoke plans to initiate a rolli

    6/30/26 8:00:00 AM ET
    $STOK
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $STOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Harrison Seth Loring

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    7/17/26 4:37:22 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Scientific Officer Mccauley Thomas

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    7/17/26 4:35:58 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Mccauley Thomas

    3 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    7/17/26 4:33:11 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Stoke Therapeutics with a new price target

    Goldman initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $44.00

    7/13/26 9:10:12 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Stoke Therapeutics with a new price target

    Wolfe Research initiated coverage of Stoke Therapeutics with a rating of Outperform and set a new price target of $40.00

    2/24/26 7:56:29 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Stoke Therapeutics with a new price target

    Guggenheim initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $60.00

    2/5/26 6:58:02 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STOK
    SEC Filings

    View All

    SEC Form 8-K filed by Stoke Therapeutics Inc.

    8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)

    6/30/26 8:02:16 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Stoke Therapeutics Inc.

    8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)

    6/4/26 4:08:29 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.

    SCHEDULE 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    5/15/26 4:16:19 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STOK
    Leadership Updates

    Live Leadership Updates

    View All

    Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer

    –Dr. McCauley brings more than 25 years of experience building high-performing R&D organizations and translating early scientific discoveries into new medicines for people with severe diseases– Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Thomas McCauley, Ph.D., has been appointed Chief Scientific Officer. Dr. McCauley joins Stoke with more than 25 years of experience leading high-performing R

    7/13/26 7:30:00 AM ET
    $STOK
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Clare Kahn, Ph.D., to its Board of Directors. "Clare brings more than three decades of industry experience, and we are very pleased to welcome her to the Board at this pivotal time for Stoke," said Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics. "Clare's deep regulatory strategy and drug development expertise, p

    4/7/26 4:01:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

    – Mr. Olson brings two decades of successful corporate business development experience with an emphasis on rare diseases and RNA therapeutics – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Ol

    9/4/24 8:00:00 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STOK
    Financials

    Live finance-specific insights

    View All

    Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

    – New 4-year longitudinal data from the Phase 1/2a open-label extension (OLE) studies provide additional support for the disease-modifying potential of zorevunersen, an investigational medicine for the treatment of Dravet syndrome – – Statistically significant improvements in cognition and behavior demonstrated at 1, 2, 3 and 4 years of treatment compared to OLE baseline, in addition to continued durability in seizure reductions – – Zorevunersen generally well tolerated, with some patients treated for more than 5 years – – Enrollment of approximately 150 patients into the Phase 3 EMPEROR study expected to complete in June 2026 to support a data readout in mid-2027; these data are anti

    5/7/26 4:01:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that management will host a webcast and conference call for analysts and investors on Thursday, May 7, 2026, at 4:30 p.m. ET, to discuss first quarter 2026 business and financial updates. The webcast will be available on the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. Research analysts who plan to join the call a

    4/30/26 4:01:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

    – Global Phase 3 EMPEROR study patient recruitment ongoing in the U.S., UK, and Japan with more than 20 patients randomized to zorevunersen or sham; Study on track to complete enrollment in second half of 2026 – – As of September 30, 2025, the Company had $328.6 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to mid-2028 – – Webcast and conference call for analysts and investors at 4:30PM Eastern Time today – Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a fi

    11/4/25 4:01:00 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:58 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Stoke Therapeutics Inc.

    SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 4:24:49 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:12 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care